BREAKING
Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 2 hours ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 4 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 6 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 7 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 7 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 8 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 10 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 10 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 11 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 11 hours ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 2 hours ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 4 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 6 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 7 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 7 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 8 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 10 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 10 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 11 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 11 hours ago
ADVERTISEMENT
AlphaGraphs

Bristol Myers Squibb (BMY) Earnings: 2Q25 Key Numbers

Bristol Myers Squibb (NYSE: BMY) reported its second quarter 2025 earnings results today. Total revenues inched up 1% year-over-year to $12.3 billion. Net earnings attributable to BMS were $1.31 billion, or $0.64 per share, compared to $1.68 billion, or $0.83 per share, last year. Adjusted EPS decreased 29% to $1.46. Bristol Myers Squibb expects full-year […]

$BMY July 31, 2025 1 min read

Bristol Myers Squibb (NYSE: BMY) reported its second quarter 2025 earnings results today.

Total revenues inched up 1% year-over-year to $12.3 billion.

Net earnings attributable to BMS were $1.31 billion, or $0.64 per share, compared to $1.68 billion, or $0.83 per share, last year. Adjusted EPS decreased 29% to $1.46.

Bristol Myers Squibb expects full-year 2025 revenue to range between $46.5-47.5 billion and adjusted EPS to range between $6.35-6.65.

Prior performance

Bristol Myers Squibb Q1 2025 earnings infographic
ADVERTISEMENT